EquityZen Growth Technology Fund LLC - Series 1680
Raised
$116K
Investors
8
Min Invest
$10,010
AltStreet Analysis
·Generated from EDGAR primary sources
EquityZen Growth Technology Fund LLC - Series 1680 is a Delaware pooled investment fund filed by EquityZen Advisors and Philip Haslett on 2023-05-15, raising $116K from 8 investors under Rule 506(b) and Section 3(c)(1). The fund carries a $10K minimum investment and is part of the EquityZen platform, which operates over 1,800 related pre-IPO SPV entities.
This pre-IPO vehicle follows the typical EquityZen platform pattern: Rule 506(b)/3(c)(1) exemptions with accessible minimums ($10K) targeting retail-accredited investors seeking exposure to private growth companies. The raise size and investor count are consistent with single-company SPV structures common in secondary pre-IPO markets.
Data Flags
EDGAR Filing Data
Form D — Primary Source
View on SEC.govRelated Persons (Form D)
Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.
EquityZen Advisors LLC
Executive Officer, Director · New York, NY
Philip Haslett
Executive Officer, Director · New York, NY
Is this your offering?
Claim this profile to add contact information, team members, LinkedIn profiles, fund history, and additional financial data. EDGAR-sourced data and AltStreet analysis cannot be edited, but corrections can be requested for verifiable inaccuracies.
Data Methodology
Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.
